info@seagull-health.com
SeagullHealth
search
Roflumilast(Daxas)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Daxas(Roflumilast) Instructions:Uses,Dosage, Side Effects
DALIRESP, with the active ingredient roflumilast, is an orally administered medication classified as a selective phosphodiesterase 4 (PDE4) inhibitor. By inhibiting PDE4, it increases intracellular cyclic AMP levels in lung cells, which is believed to mediate anti-inflammatory effects. It is not a bronchodilator and therefore does not provide immediate relief for acute breathing difficulties. The product is supplied as 250 mcg and 500 mcg film-coated tablets and is marketed by AstraZeneca Pharmaceuticals LP for a specific subset of COPD patients.
DALIRESP® is indicated as a treatment to reduce the risk of Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. It is not a bronchodilator and is not indicated for the relief of acute bronchospasm.
One 500 mcg tablet taken orally once daily, with or without food.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
